Mathieu Lupien, PhD
Researchers have mapped the impact of an acquired mutation that alters the epigenetic identity in about 50% of prostate tumor samples, according to results published in Nature Genetics. The TMPRSS2 and ERG genes can change the epigenetic identity of tumors, leading to some of these genes being turned on while others remain off, explained Mathieu Lupien, PhD.
, Lupien, senior scientist at the Princess Margaret Cancer Centre and Ontario Institute for Cancer Research, discussed this analysis of the influence of mutations on the epigenetics of prostate cancer.
OncLive: Please provide some background of your research.
: We had the chance to work on this as part of the Canadian Prostate Cancer Genome. This research involved patients with prostate cancer who had intermediate-risk disease and might progress. They had been profiled on the genetic level by our collaborators in the past. Their status was a common fusion between the TMPRSS2 gene and the ERG gene, generating a T2E fusion-positive subtype.
... to read the full story